MacuCLEAR

What MacuCLEAR does

MacuCLEAR is a private biotechnology company headquartered in Plano, Texas, founded in 2006, that focuses on discovering and developing novel therapeutics for vascular disorders of the eye. The therapeutic area typically encompasses conditions such as age-related macular degeneration, diabetic retinopathy, and other ischemic ocular diseases where retinal vasculature plays a central pathogenic role. Consistent with a discovery/clinical-stage biotech operating model, MacuCLEAR's revenue mechanics, if any, would be expected to flow through licensing arrangements, R&D collaborations, grant funding, or future milestone payments rather than commercial product sales — though the available source data discloses no pipeline assets, partnerships, or commercial transactions of any kind.

The company is associated with a single disclosed funding event — a $1,000,000 round dated January 3, 2012, with investors and lead investor undisclosed — and with one named co-founder, George Chiou. Reported headcount sits in the 11-50 range. No products, services, patents, trademarks, certifications, customers, alliances, management roster, or geographic footprint is documented in any cited source.

The available source material presents material integrity issues that any analyst should price in. The dominant structured source is a HugeDomains.com marketplace listing offering the domain MacuClear.com for resale at $1,495, not an active corporate disclosure; firmographic descriptors (founding year, location, headcount, therapeutic focus) come from a separate, unlabeled profile block. The combination of a decade-old last funding touch, no recent corporate-channel disclosures, and a primary domain actively listed for sale is consistent with dormancy, restructuring, or wind-down, and substantially limits the reliability of any forward-looking read on the company.

Name

MacuCLEAR

Website

https://macuclear.com

Company type

Private

Founded year

2006

Headcount range

11–50 employees

Short description

MacuCLEAR is a Plano, Texas-based private biotechnology company, founded in 2006, focused on discovering and developing novel therapeutics for vascular disorders of the eye, with 11-50 employees and minimal disclosed funding history.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Retina & Vitreous Specialists (HLAKAKAE), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

Keywords

• Ophthalmic therapeutics
• Vascular eye disorders
• Retinal drug development
• Ocular pharmaceuticals
• Eye disease treatments

Headquarters

HQ city

Plano

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Pricing tiers

Core offering

MacuCLEAR focuses on discovering and developing novel solutions for vascular disorders of the eye. The company operates as a small, private biotechnology R&D entity based in Plano, Texas, working on therapeutics for ophthalmic vascular conditions. Specific named drug candidates, indications, and clinical-stage assets are not described in the available source data.

Product overview

MacuClear.com is a domain name being sold through HugeDomains.com marketplace. The domain itself is the only product or service referenced in the available source material. No specific product portfolio, modules, or related offerings for MacuCLEAR as a company are described in this source. The offering consists solely of the domain name transfer, with optional WhoIs Privacy Protection available through the registrar NameBright.com.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Graybug Vision: Develops sustained-release ocular drug delivery for retinal diseases. Comparable as a small ophthalmic specialty pharma targeting chronic retinal disorders.
• Alimera Sciences: Specialty ophthalmic pharmaceutical company focused on retinal diseases, including diabetic macular edema. Highly comparable to MacuCLEAR's vascular-retinal therapeutic focus as a small, focused ophthalmic drug developer.
• IVERIC bio (formerly Ophthotech): Develops therapeutics for retinal diseases, including AMD. Directly comparable as a small-cap ophthalmic drug developer targeting retinal vascular pathology.
• Clearside Biomedical: Specialty ophthalmic company developing therapeutics for retinal and choroidal diseases using suprachoroidal drug delivery. Comparable as a small-cap ophthalmic drug developer addressing serious retinal conditions.
• Neurotech Pharmaceuticals: Private ophthalmic biotech developing encapsulated cell therapy for retinal diseases including macular telangiectasia and glaucoma. Comparable as a small R&D-stage ophthalmic company.
• Allegro Ophthalmics: Private ophthalmic biotech developing small-molecule integrin peptide therapies for retinal vascular diseases including diabetic macular edema. Comparable therapeutic focus on vascular retinal disorders.

Emerging players

• PanOptica: Private ophthalmic drug development company focused on retinal diseases including AMD. Comparable as a small, focused ophthalmic R&D-stage company.

Broad incumbents

• Regeneron Pharmaceuticals: Sells Eylea (aflibercept), the market-leading anti-VEGF therapy for wet AMD and other retinal vascular conditions. Broad incumbent defining the competitive landscape MacuCLEAR would operate within.
• Genentech (Roche): Develops and markets Lucentis and Susvimo for retinal vascular diseases including AMD. Broad incumbent competitor in the vascular ophthalmology space.
• Apellis Pharmaceuticals: Specialty ophthalmic pharmaceutical company marketing Syfovre (pegcetacoplan) for geographic atrophy and other retinal disease therapies. Comparable as a commercial-stage ophthalmic specialty pharma targeting macular disease.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

• Xx.com/MacuCLEAR
• Facebookfacebook.com/MacuCLEAR
• LinkedInlinkedin.com/company/2390339

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MacuCLEAR